AstraZeneca and Global Transparency
Our Approach
AstraZeneca strongly believes that interactions with Health Care Providers (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research.
To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information.
HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.
We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate treatment options.
We believe that regulations such as US Open Payments, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure code, and others across the globe, which require companies to disclose payments and transfers of value made to HCPs and HCOs, will provide greater transparency around these already well-regulated relationships.
Disclosure of Payments and Transfers
The payments and transfers of value disclosed here were made for activities such as providing professional advice about how medicines are used in practice, sharing professional expertise at medical education meetings, taking part in advisory boards, research and educational grants.
Europe
To download the assumptions and interpretations of the Disclosure Code for each of our markets, and to download market-level disclosure reports, please click on the country links below.
The EFPIA Disclosure Code 2017 Self Certification Letter affirms AstraZeneca’s commitment to the principles of the EFPIA Disclosure Code.
Austria
Belgium
Bulgaria
2017
2016
Croatia
Cyprus
Czech Republic
Denmark
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Estonia
Finland
France
2017
2017 EFPIA Disclosure (PDF 202kb)
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Germany
Greece
Hungary
2017
2016
Iceland
There are no payments/transfers of value to disclose.
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Norway
2017
2016
Poland
Portugal
Romania
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Russia
Serbia
Slovakia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Slovenia
2017
2016
Spain
Sweden
2017
2016
Switzerland
2017
2016
Turkey
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Ukraine
United Kingdom
US
For information about US Open Payments, please visit our Physician engagement page or the US Open Payments page managed by the Centers for Medicaid and Medicare Services (CMS).
Asia Pacific
Australia
Indonesia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Philippines
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Latin America
Brazil State of Minas Gerais
Middle East & Africa
Saudi Arabia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Last updated January 2019